These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16210960)

  • 41. Outcome of Kaposi's sarcoma and graft following discontinuation of immunosuppressive drugs in renal transplant recipients.
    Firoozan A; Hosseini Moghaddam SM; Einollahi B; Pour-Reza-Gholi F; Nafar M; Basiri A; Ebrahimi-Rad R
    Transplant Proc; 2005 Sep; 37(7):3061-4. PubMed ID: 16213305
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reduced intrapatient variability of cyclosporine pharmacokinetics in renal transplant recipients switched from oral Sandimmune to Neoral.
    Mendez R; Abboud H; Burdick J; Copley B; Freeman R; Batiuk TD; Cooney GF; Barbeito R
    Clin Ther; 1999 Jan; 21(1):160-71. PubMed ID: 10090433
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Conversion from Brand-Name Neoral to the Generic Ciqorin in Stable Renal Transplant Recipients.
    Cortinovis M; Gotti E; Trillini M; Carrara F; Gaspari F; Ruggenenti P; Remuzzi G; Perico N
    Nephron; 2017; 135(3):173-180. PubMed ID: 27941326
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Incidence and clinical predictors of Kaposi's sarcoma among 1721 Italian solid organ transplant recipients: a multicenter study.
    Tessari G; Naldi L; Boschiero L; Cordiano C; Piaserico S; Fortina AB; Cerimele D; La Parola IL; Capuano M; Gotti E; Ruggenenti P; Sassi F; Remuzzi G; Girolomoni G
    Eur J Dermatol; 2006; 16(5):553-7. PubMed ID: 17101478
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Converting renal transplant patients maintained on Sandimmune to a new microemulsion formulation, Sandimmune Neoral.
    Chu SH; Pang ST; Chiang YJ; Chuang CK; Chen HW; Chen CS; Chou CC; Huang CC
    Transplant Proc; 1998 Nov; 30(7):3521-3. PubMed ID: 9838543
    [No Abstract]   [Full Text] [Related]  

  • 46. Regression of post-transplant Kaposi's sarcoma using sirolimus.
    Kolhe N; Mamode N; Van der Walt J; Pattison J
    Int J Clin Pract; 2006 Nov; 60(11):1509-12. PubMed ID: 16787440
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetic study of the new cyclosporine-A formulation (Neoral) in adult allogeneic bone marrow transplant recipients.
    Dotti G; Gaspari F; Caruso R; Perico N; Remuzzi G; Barbui T; Rambaldi A
    Haematologica; 2001 Mar; 86(3):311-5. PubMed ID: 11255279
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunosuppressive therapy and Kaposi's sarcoma after kidney transplantation.
    Moray G; Başaran O; Yağmurdur MC; Emiroğlu R; Bilgin N; Haberal M
    Transplant Proc; 2004; 36(1):168-70. PubMed ID: 15013336
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reversal of cyclosporine malabsorption in diabetic recipients of simultaneous pancreas and kidney transplant using a microemulsion formulation.
    Chapman JR; O'Connell PJ; Bovington KJ; Allen RD
    Transplantation; 1996 Jun; 61(12):1699-704. PubMed ID: 8685946
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Conversion from once-daily Sandimmune cyclosporine to once-daily Neoral in renal transplant patients.
    Arvind C; Vathsala A; Woo KT
    Transplant Proc; 2000 Nov; 32(7):1681-2. PubMed ID: 11119890
    [No Abstract]   [Full Text] [Related]  

  • 51. Potential clinical implications of substitution of generic cyclosporine formulations for cyclosporine microemulsion (Neoral) in transplant recipients.
    Johnston A; Belitsky P; Frei U; Horvath J; Hoyer P; Helderman JH; Oellerich M; Pollard S; Riad H; Rigotti P; Keown P; Nashan B
    Eur J Clin Pharmacol; 2004 Aug; 60(6):389-95. PubMed ID: 15205865
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Resolution of diffuse skin and systemic Kaposi's sarcoma in a renal transplant recipient after introduction of everolimus: a case report.
    Detroyer D; Deraedt K; Schöffski P; Hauben E; Lagrou K; Naesens M; Delforge ML; Kuypers D
    Transpl Infect Dis; 2015 Apr; 17(2):303-7. PubMed ID: 25645490
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Kaposi's sarcoma in kidney transplant recipients: a 23-year experience.
    Moosa MR
    QJM; 2005 Mar; 98(3):205-14. PubMed ID: 15728402
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and tolerability of Neoral vs Sandimmune: 1-year data in primary renal allograft recipients. Neoral Study Group.
    Barone G; Bunke CM; Choc MG; Hricik DE; Jin JH; Klein JB; Marsh CL; Min DI; Pescovitz MD; Pollak R; Pruett TL; Stinson JB; Thompson JS; Vasquez E; Waid T; Wombolt DG; Wong RL
    Transplant Proc; 1996 Aug; 28(4):2183-6. PubMed ID: 8769194
    [No Abstract]   [Full Text] [Related]  

  • 55. Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine.
    Stegall MD; Simon M; Wachs ME; Chan L; Nolan C; Kam I
    Transplantation; 1997 Dec; 64(12):1695-700. PubMed ID: 9422404
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cyclosporin A (Neoral) in pediatric organ transplantation. Neoral Pediatric Study Group.
    Hoyer PF
    Pediatr Transplant; 1998 Feb; 2(1):35-9. PubMed ID: 10084758
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Investigation of the pharmacokinetics of cyclosporine in patients following long-term administration after a kidney transplant: comparison of Neoral and Sandimmune.
    Takahara S; Ichimaru N; Kojima Y; Namba Y; Toki K; Shi Y; Yoshimura K; Matsumiya K; Nonomura N; Okuyama A
    Transplant Proc; 2004 Mar; 36(2 Suppl):456S-460S. PubMed ID: 15041387
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Estimation of mean relative bioavailability of cyclosporine Sandimmune and Neoral using NONMEM in renal transplant recipients.
    Lee KL; Lee KT; Chung HM; Lin YP
    Transplant Proc; 1998 Nov; 30(7):3526-9. PubMed ID: 9838545
    [No Abstract]   [Full Text] [Related]  

  • 59. Cyclosporine A lipid nanoparticles for oral administration: Pharmacodynamics and safety evaluation.
    Guada M; Lana H; Gil AG; Dios-Viéitez Mdel C; Blanco-Prieto MJ
    Eur J Pharm Biopharm; 2016 Apr; 101():112-8. PubMed ID: 26877154
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Successful treatment with liposomal doxorubicin and foscarnet in a patient with widespread Kaposi's sarcoma and human herpes virus 8-related, serious hemophagocytic syndrome, after renal transplantation].
    Bossini N; Sandrini S; Setti G; Luppi M; Maiorca P; Maffei C; Cancarini G
    G Ital Nefrol; 2005; 22(3):281-6. PubMed ID: 16001371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.